{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:01:48Z","timestamp":1778770908678,"version":"3.51.4"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health and Welfare","award":["MOHW111-TDU-B-221-114009"],"award-info":[{"award-number":["MOHW111-TDU-B-221-114009"]}]},{"name":"Ministry of Health and Welfare","award":["109-2320-B-182A-011"],"award-info":[{"award-number":["109-2320-B-182A-011"]}]},{"name":"Ministry of Health and Welfare","award":["CMRPG3J0963"],"award-info":[{"award-number":["CMRPG3J0963"]}]},{"name":"Ministry of Health and Welfare","award":["CMRPG3K0412"],"award-info":[{"award-number":["CMRPG3K0412"]}]},{"name":"Ministry of Health and Welfare","award":["CMRPG3E0673"],"award-info":[{"award-number":["CMRPG3E0673"]}]},{"name":"Ministry of Science and Technology","award":["MOHW111-TDU-B-221-114009"],"award-info":[{"award-number":["MOHW111-TDU-B-221-114009"]}]},{"name":"Ministry of Science and Technology","award":["109-2320-B-182A-011"],"award-info":[{"award-number":["109-2320-B-182A-011"]}]},{"name":"Ministry of Science and Technology","award":["CMRPG3J0963"],"award-info":[{"award-number":["CMRPG3J0963"]}]},{"name":"Ministry of Science and Technology","award":["CMRPG3K0412"],"award-info":[{"award-number":["CMRPG3K0412"]}]},{"name":"Ministry of Science and Technology","award":["CMRPG3E0673"],"award-info":[{"award-number":["CMRPG3E0673"]}]},{"name":"Chang Gung Memorial Hospital","award":["MOHW111-TDU-B-221-114009"],"award-info":[{"award-number":["MOHW111-TDU-B-221-114009"]}]},{"name":"Chang Gung Memorial Hospital","award":["109-2320-B-182A-011"],"award-info":[{"award-number":["109-2320-B-182A-011"]}]},{"name":"Chang Gung Memorial Hospital","award":["CMRPG3J0963"],"award-info":[{"award-number":["CMRPG3J0963"]}]},{"name":"Chang Gung Memorial Hospital","award":["CMRPG3K0412"],"award-info":[{"award-number":["CMRPG3K0412"]}]},{"name":"Chang Gung Memorial Hospital","award":["CMRPG3E0673"],"award-info":[{"award-number":["CMRPG3E0673"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>(1) Background: The C-ros oncogene 1 (ROS1) gene translocation is an important biomarker for selecting patients for crizotinib-targeted therapy. The aim of this study was to understand the incidence, diagnostic algorithm, clinical course and objective response to crizotinib in ROS1 translocated lung non-small cell lung cancers (NSCLCs) in Taiwan. (2) Methods: First, we retrospectively studied the ROS1 status in 100 NSCLC samples using break-apart fluorescent in situ hybridization (FISH) and immunohistochemical (IHC) staining to establish a diagnostic algorithm. Then, we performed routine ROS1 IHC tests in 479 NSCLCs, as crizotinib was available from 2018 in Taiwan. We analyzed the objective response rate and the survival impact of crizotinib. (3) Results: Four ROS1 translocations were clustered in epidermal growth factor receptor (EGFR) wild-type adenocarcinomas but not in cases with EGFR mutations. Strong ROS1 expression was positively correlated with ROS1 translocation (p &lt; 0.001). NSCLCs with ROS1 translocation had a poor prognosis compared to those without ROS1 translocation (p = 0.004) in the pre-crizotinib stage. Twenty NSCLCs were detected with ROS1 translocation in 479 wild-type EGFR specimens from 2018. Therefore, the incidence of ROS1 translocation is approximately 4.18% in EGFR wild-type NSCLCs. In these 20 ROS1 translocation cases, 19 patients received crizotinib treatment, with an objective response rate (ORR) of 78.95% (confidence interval = 69.34% to 88.56%), including 1 complete response, 14 partial responses, 3 stable cases and 1 progressive case. Overall survival and progression-free survival were better in the 19 ROS1-translocated NSCLCs of the prospective group with crizotinib treatment than the four ROS1-translocated NSCLCs of the retrospective group without crizotinib treatment. (4) Conclusions: ROS1-translocated NSCLCs had a poor prognosis and could have a beneficial outcome with crizotinib.<\/jats:p>","DOI":"10.3390\/ijms23105789","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T09:18:08Z","timestamp":1653124688000},"page":"5789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan"],"prefix":"10.3390","volume":"23","author":[{"given":"Hsiang-Sheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department & Centers of Lung Cancer and Interventional Bronchoscopy, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Chi","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-0862","authenticated-orcid":false,"given":"Tsai-Hsien","family":"Hung","sequence":"additional","affiliation":[{"name":"Institute of Stem Cell & Translational Cancer Research, Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwai-Fong","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-7328","authenticated-orcid":false,"given":"Tse-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University School of Medicine, Kwei-Shan, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2147\/OTT.S134382","article-title":"Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: Systematic review and network meta-analysis","volume":"10","author":"Batson","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non\u2013small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","article-title":"Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)","volume":"137","author":"Gelatti","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_5","first-page":"2020","article-title":"Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives","volume":"17","author":"Cao","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fphys.2019.00216","article-title":"Discovery stories of RET fusions in lung cancer: A mini-review","volume":"10","author":"Takeuchi","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/cncr.27940","article-title":"KIF5B-RET fusions in Chinese patients with non\u2013small cell lung cancer","volume":"119","author":"Cai","year":"2013","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort","volume":"33","author":"Zalcman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2217\/fon-2016-0050","article-title":"ROS1 fusions in cancer: A review","volume":"12","author":"Uguen","year":"2016","journal-title":"Future Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.22212","article-title":"Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR","volume":"53","author":"Cavalloni","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non\u2013small cell lung cancer","volume":"13","author":"Li","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1158\/1078-0432.CCR-12-0550","article-title":"Identifying and targeting ROS1 gene fusions in non\u2013small cell lung cancer","volume":"18","author":"Davies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/his.12379","article-title":"ROS 1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases","volume":"65","author":"Warth","year":"2014","journal-title":"Histopathology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3727\/096504019X15509372008132","article-title":"Different types of ROS1 fusion partners yield comparable efficacy to crizotinib","volume":"27","author":"He","year":"2019","journal-title":"Oncol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shan, L., Lian, F., Guo, L., Qiu, T., Ling, Y., Ying, J., and Lin, D. (2015). Detection of ROS1 gene rearrangement in lung adenocarcinoma: Comparison of IHC, FISH and real-time RT-PCR. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120422"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/1759-7714.12899","article-title":"Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_24","first-page":"300","article-title":"Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: A meta-analysis","volume":"4","author":"Zhu","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Arai, Y., Totoki, Y., Takahashi, H., Nakamura, H., Hama, N., Kohno, T., Tsuta, K., Yoshida, A., Asamura, H., and Mutoh, M. (2013). Mouse model for ROS1-rearranged lung cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056010"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/JTO.0b013e3182a4dd6e","article-title":"Clinicopathologic analysis of ROS1-rearranged non\u2013small-cell lung cancer and proposal of a diagnostic algorithm","volume":"8","author":"Go","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","first-page":"639","article-title":"Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation","volume":"44","author":"Zhong","year":"2015","journal-title":"Chin. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/annonc\/mdt071","article-title":"ROS1 fusions in Chinese patients with non-small-cell lung cancer","volume":"24","author":"Cai","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_29","first-page":"1","article-title":"ROS1 gene fusion in advanced lung cancer in women: A systematic analysis, review of the literature, and diagnostic algorithm","volume":"1","author":"Marchetti","year":"2017","journal-title":"Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fu, S., Liang, Y., Lin, Y.-B., Wang, F., Huang, M.-Y., Zhang, Z.-C., Wang, J., Cen, W.-J., and Shao, J.-Y. (2015). The frequency and clinical implication of ROS1 and RET rearrangements in resected stage IIIA-N2 non-small cell lung cancer patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124354"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00428-014-1679-2","article-title":"ROS1 gene rearrangement and copy number gain in non-small cell lung cancer","volume":"466","author":"Jin","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/modpathol.2013.192","article-title":"Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers","volume":"27","author":"Yoshida","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1245\/s10434-012-2553-6","article-title":"ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms","volume":"20","author":"Lee","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: A review with recommendations","volume":"469","author":"Bubendorf","year":"2016","journal-title":"Virchows Arch."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jtho.2017.01.004","article-title":"ROS1 fusions rarely overlap with other oncogenic drivers in non\u2013small cell lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/PAS.0b013e3182960fa7","article-title":"ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas","volume":"37","author":"Sholl","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/arpa.2019-0085-OA","article-title":"Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization","volume":"144","author":"Huang","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.lungcan.2014.01.003","article-title":"Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma","volume":"83","author":"Kim","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20388","DOI":"10.18632\/oncotarget.3981","article-title":"ROS1 amplification mediates resistance to gefitinib in glioblastoma cells","volume":"6","author":"Aljohani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non\u2013small cell lung cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"v637","DOI":"10.1093\/annonc\/mdz260.070","article-title":"Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial\u2014Updated progression-free survival, overall survival and mechanisms of resistance","volume":"30","author":"Michels","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1200\/jco.2015.33.15_suppl.8065","article-title":"Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACS\u00e9 phase II trial","volume":"33","author":"Faivre","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non\u2013small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1158\/1078-0432.CCR-04-1245","article-title":"High frequency of epidermal growth factor receptor mutations with complex patterns in non\u2013small cell lung cancers related to gefitinib responsiveness in Taiwan","volume":"10","author":"Huang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_46","first-page":"131","article-title":"Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features","volume":"9","author":"Cao","year":"2016","journal-title":"OncoTargets Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:16:11Z","timestamp":1760138171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105789"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105789","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]}}}